ALSO NOTED: Dyadic CEO on leave as company probes operations; Singulair OK'd for new condition; and much more...

> The CEO and chairman of Dyadic International, Mark A. Emalfarb, has gone on leave as the company announced it is investigating potential financial improprieties in its operations in China. Release

> The FDA has issued an approvable letter for Wyeth's osteoporosis drug Viviant. Final approval is contingent on a final review of new data from a recently completed late-stage trial. Release

> Wyeth and the Irish government have announced a joint $32 million project to improve the drug developer's R&D operations. Report

> Merck's Singulair has been approved for exercise-induced asthma. Release

> Sciele Pharma is buying Alliant Pharmaceuticals, a pediatric specialty pharma company, for $122 million. Release

> Bavarian Nordic has received an order for 20 million doses of its smallpox vaccine from the U.S. government. Report

> Paladin Labs is buying BioEnvelope for $1.9 million. Paladin gains BioEnvelop's rapidly dissolving film strip technology. Report

> A researcher at Purdue University laboratory is working on a compound that he says could become the first treatment available for Alzheimer's. Report

> A Johns Hopkins University research team has developed a synthetic drug based on a Chinese herbal folk remedy that cured malaria-infected mice with a single shot. Report

And Finally... A new study indicates that migraines may actually help prevent people from suffering memory loss. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.